Cancers in which pathological changes in PD1/PD-L expression have been identified include melanoma [134,135], chronic myelogenous leukemia [136,137] and lymphocytic leukemia, ovarian cancer [138,139], NSCLC [140,141], and Hodgkin’s lymphoma [142]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.